Reversine exhibits antineoplastic activity in JAK2
Apoptosis
Aurora Kinase A
/ genetics
Aurora Kinase B
/ genetics
Biomarkers, Tumor
/ genetics
Cell Cycle
Cell Proliferation
Gene Expression Regulation, Neoplastic
/ drug effects
Humans
Janus Kinase 2
/ genetics
Morpholines
/ pharmacology
Mutation
Myeloproliferative Disorders
/ genetics
Protein Kinase Inhibitors
Purines
/ pharmacology
Tumor Cells, Cultured
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
09 07 2019
09 07 2019
Historique:
received:
19
12
2018
accepted:
21
06
2019
entrez:
11
7
2019
pubmed:
11
7
2019
medline:
28
10
2020
Statut:
epublish
Résumé
JAK2/STAT signaling participates in the Ph-negative myeloproliferative neoplasms (MPN) pathophysiology and has been targeted by ruxolitinib, a JAK1/2 inhibitor. In the present study, the impact of ruxolitinib treatment on cytoskeleton-related genes expression was explored. In SET2 cells, AURKA and AURKB expression/activity were downregulated in a dose- and time-dependent manner by ruxolitinib. Reversine, a multikinase inhibitor selective for aurora kinases, reduced cell viability in a dose- and/or time-dependent manner in JAK2
Identifiants
pubmed: 31289316
doi: 10.1038/s41598-019-46163-2
pii: 10.1038/s41598-019-46163-2
pmc: PMC6616334
doi:
Substances chimiques
Biomarkers, Tumor
0
Morpholines
0
Protein Kinase Inhibitors
0
Purines
0
JAK2 protein, human
EC 2.7.10.2
Janus Kinase 2
EC 2.7.10.2
AURKA protein, human
EC 2.7.11.1
AURKB protein, human
EC 2.7.11.1
Aurora Kinase A
EC 2.7.11.1
Aurora Kinase B
EC 2.7.11.1
2-(4-morpholinoanilino)-6-cyclohexylaminopurine
Z499CLJ023
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9895Références
Br J Haematol. 2010 Jul;150(1):46-57
pubmed: 20507304
FEBS Lett. 2011 Jun 23;585(12):1884-90
pubmed: 21557940
Nat Med. 2010 Apr;16(4):483-9
pubmed: 20228816
Cell Cycle. 2008 Feb 15;7(4):533-41
pubmed: 18431843
Eur J Med Chem. 2017 Nov 10;140:1-19
pubmed: 28918096
Nat Med. 2015 Dec;21(12):1473-80
pubmed: 26569382
Nat Rev Cancer. 2007 Sep;7(9):673-83
pubmed: 17721432
Leuk Res. 2016 Sep;48:26-31
pubmed: 27447890
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
Oncotarget. 2015 Oct 6;6(30):29573-84
pubmed: 26356819
Leukemia. 2011 Feb;25(2):218-25
pubmed: 21079613
Eur J Haematol. 2011 Jul;87(1):54-60
pubmed: 21447007
Sci Rep. 2018 Aug 7;8(1):11821
pubmed: 30087398
J Clin Med Res. 2015 Oct;7(10):742-51
pubmed: 26345296
PLoS One. 2015 Mar 17;10(3):e0114363
pubmed: 25781882
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Leukemia. 2018 May;32(5):1057-1069
pubmed: 29515238
Mol Cancer Ther. 2008 May;7(5):1140-9
pubmed: 18483302
N Engl J Med. 2006 Dec 7;355(23):2452-66
pubmed: 17151367
Breast Cancer. 2014 May;21(3):358-69
pubmed: 22926505
Mol Cancer Ther. 2007 Jun;6(6):1851-7
pubmed: 17541033
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Cell Death Differ. 2007 Feb;14(2):378-80
pubmed: 16841088
Nat Commun. 2011;2:316
pubmed: 21587233
J Biomed Sci. 2012 Jan 27;19:9
pubmed: 22283874
Leukemia. 2000 Jan;14(1):142-52
pubmed: 10637490
J Cell Mol Med. 2013 Feb;17(2):265-76
pubmed: 23301855
Trends Cell Biol. 2018 Oct;28(10):776-792
pubmed: 29871823
J Cell Biol. 2010 Jul 12;190(1):73-87
pubmed: 20624901
J Hematol Oncol. 2009 Dec 29;2:51
pubmed: 20040095
J Clin Invest. 2018 Jan 2;128(1):387-401
pubmed: 29200404
J Cell Biochem. 2012 Oct;113(10):3207-17
pubmed: 22615034
Blood. 2010 Apr 8;115(14):2882-90
pubmed: 20068225
Blood. 2010 Feb 18;115(7):1416-24
pubmed: 20008792
Cell Mol Life Sci. 2006 Dec;63(24):2939-53
pubmed: 17131059
Int J Oncol. 2007 Dec;31(6):1293-300
pubmed: 17982654
Cancer Cell. 2015 Jul 13;28(1):15-28
pubmed: 26175413
N Engl J Med. 1993 Mar 4;328(9):614-9
pubmed: 8429853
Expert Rev Anticancer Ther. 2006 Jan;6(1):109-20
pubmed: 16375648
Science. 1982 Jun 11;216(4551):1233-5
pubmed: 6177045